Highstreet Asset Management Inc. boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 25.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 12,358 shares of the company’s stock after buying an additional 2,474 shares during the period. Highstreet Asset Management Inc.’s holdings in Eli Lilly and were worth $1,057,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Eli Lilly and by 2.3% during the second quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock worth $5,778,109,000 after purchasing an additional 1,610,885 shares during the period. BlackRock Inc. grew its holdings in shares of Eli Lilly and by 2.1% during the second quarter. BlackRock Inc. now owns 63,583,747 shares of the company’s stock valued at $5,232,942,000 after buying an additional 1,323,259 shares in the last quarter. State Street Corp grew its holdings in shares of Eli Lilly and by 1.6% during the first quarter. State Street Corp now owns 42,363,935 shares of the company’s stock valued at $3,563,230,000 after buying an additional 651,424 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of Eli Lilly and by 7,093.5% during the second quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock valued at $769,774,000 after buying an additional 9,223,251 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Eli Lilly and by 8.4% during the first quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock valued at $764,597,000 after buying an additional 708,597 shares in the last quarter. 76.43% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company (NYSE:LLY) traded down $0.74 during trading on Thursday, reaching $85.32. The company’s stock had a trading volume of 3,130,900 shares, compared to its average volume of 3,670,362. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. The firm has a market cap of $94,760.24, a PE ratio of 21.04, a price-to-earnings-growth ratio of 1.89 and a beta of 0.35. Eli Lilly and Company has a 12-month low of $66.39 and a 12-month high of $89.09.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating the consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The company had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. During the same period in the prior year, the company posted $0.88 EPS. The company’s revenue was up 9.0% compared to the same quarter last year. sell-side analysts expect that Eli Lilly and Company will post 4.21 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.44%. Eli Lilly and’s dividend payout ratio (DPR) is presently 98.58%.

In related news, major shareholder Lilly Endowment Inc sold 205,000 shares of Eli Lilly and stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $86.81, for a total transaction of $17,796,050.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Susan Mahony sold 36,585 shares of Eli Lilly and stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $86.18, for a total value of $3,152,895.30. Following the transaction, the senior vice president now owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 628,588 shares of company stock worth $53,399,536. 0.20% of the stock is owned by corporate insiders.

A number of brokerages have recently weighed in on LLY. BMO Capital Markets set a $73.00 price target on Eli Lilly and and gave the company a “sell” rating in a report on Tuesday. Morgan Stanley boosted their target price on Eli Lilly and from $86.00 to $90.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 21st. Zacks Investment Research downgraded Eli Lilly and from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Berenberg Bank restated a “buy” rating and issued a $98.00 target price on shares of Eli Lilly and in a research note on Thursday, October 26th. Finally, Leerink Swann boosted their target price on Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the company. Eli Lilly and presently has an average rating of “Hold” and a consensus target price of $90.25.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://theolympiareport.com/2017/12/07/highstreet-asset-management-inc-boosts-holdings-in-eli-lilly-and-company-lly.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.